
|Articles|June 1, 2003
- Psychiatric Times Vol 20 No 6
- Volume 20
- Issue 6
After the Famous Poet
Poetry of the Times
Advertisement
After the Famous Poet
recites a poem
that ends with "a purple stain,"
she recalls how she went to war
with another famous poet
about whether it is proper
to end a poem with a color.
And I envy the famous poet
for living in a world
where battles over colorful words
can feel like life and death.
For years ago I chose a world
where colorful words
like "green meconium stain"
or "peau d'orange"
describe deformity beyond metaphor,
a war where flesh is cut and colored
to let us read the body's text,
our precise choice of words
as brilliant and final
as the last line of any poem.
Articles in this issue
over 23 years ago
Confidentiality Under Fireover 23 years ago
Stigma Continues in Hollywoodover 23 years ago
The Art of the Unconsciousover 23 years ago
Psychiatrists Strive to Assure Patients' Safetyover 23 years ago
Conference Probes Pathology of Self-Awarenessover 23 years ago
Music Therapy With Emotionally Disturbed Childrenover 23 years ago
The Assessment of Danger in Everyday Practiceover 23 years ago
The Other Side of the Storyover 23 years ago
Using Creativity to Explore in PsychotherapyAdvertisement
Related to this article

FDA aligns with Cognition on a phase 3 zervimesine trial for Lewy body dementia, testing 100 mg daily for 9 months to target hallucinations.

Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.

UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.

When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.

The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.

A psychiatry resident and APA Diversity Leadership Fellow explains how social history, open talk about stigma, and bilingual videos can widen access to care.

Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
Advertisement
Advertisement
Trending on Psychiatric Times
1
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
2
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
3
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
4
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
5

